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Background
The presence of myocardial late gadolinium enhancement
(LGE) in patients with sarcoidosis is a powerful predictor
of major adverse events (MAE: death, ventricular tachy-
cardia, or appropriate ICD therapy). In this study, we aim
to determine if the burden of LGE, left ventricular (LV)
and right ventricular (RV) end-diastolic and end-systolic
volume index (EDVi & ESVi) and ejection fraction (EF)
can be used to improve risk stratification in patients with
cardiac sarcoidosis (CS).
Methods
We identified 25 consecutive subjects with a diagnosis
of CS (biopsy-proven extra-cardiac sarcoidosis and pre-
sence of LGE on cardiovascular magnetic resonance).
Imaging was performed on a 1.5T scanner. Short axis
cines (6 mm thickness, 4 mm gap, temporal resolution
< 40 ms) spanning the entire LV were acquired to deter-
mine LV and RV volumes. Short axis slices were also
obtained 10 minutes after contrast (gadodiamide 0.15
mmol/kg) using a phase sensitive inversion recovery
reconstruction. LGE was identified on each slice as regions
with signal intensity (SI) > 5 standard deviations above the
mean SI of normal remote myocardium. The total amount
of LGE as a percentage of LV mass (%LGE) was deter-
mined using Diagnosoft Virtue software (Figure 1). Medi-
cal records were reviewed to identify MAE. Area under
the curve (AUC) was determined from receiver-operator
characteristics demonstrating the ability of %LGE,
LVEDVi, LVESVi, LVEF, RVEDVi, RVESVi, and RVEF to
detect MAE. Patients were divided into 2 groups; with
MAE and without MAE. Each parameter was evaluated
using unpaired T-tests. Continuous variables are presented
as mean ± standard deviation.
Results
The mean age was 58 ± 7 years, 18 (72%) were female.
Mean follow up was 39 ± 15 months. Six (24%) of
patients had MAE. There was a significant difference in
%LGE, RVEF and RVESVi but not LVEF, LVESVi,
LVEDVi or RVEDVi between those who had MAE and
those who did not (Table 1). The AUC for each of the
following parameter’s ability to predict MAE was: LVEF
0.54, LVEDVi 0.58, LVESVi 0.62, LGE 0.67, RVEDVi
0.76, RVESVi 0.85, and RVEF 0.56. Notably, in terms of
predicting death, the AUC for %LGE, RVEDVi and
RVESVi were high at 0.87, 0.86 and 0.89 respectively,
while that for LVEF was 0.61, RVEF 0.61, LVEDVi 0.54
and LVESVi 0.55.
Conclusions
The burden of LGE and RV size and function (not LV
size and function) further improve prediction of death
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Figure 1 Diagnosoft Virtue software was used to delineate areas of LGE (defined here as having a signal intensity > 5 standard
deviations above that of normal remote myocardium).
Table 1 Functional and structural parameters for subjects with and without major adverse events
MAE + MAE - P value
LVEF (%) 59 ± 4 60 ± 4 0.53
LVEDVi (ml/m2) 65 ± 22 27 ± 9 0.53
LVESVi (ml/m2) 27 ± 9 28 ± 7 0.72
RVEF (%) 42 ± 12 54 ± 9 0.01
RVEDVi (ml/m2) 86 ± 22 72 ± 14 0.09
RVESVi (ml/m2) 54 ± 18 34 ± 14 0.007
LGE (%) 20 ± 20 7 ± 5 0.01
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